Wortmannin

目录号:S2758 别名: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin是一种首次命名的PI3K抑制剂,在无细胞试验中IC50为3 nM,对 PI3K 家族的选择性较低。也会抑制自噬体的形成,并有效抑制DNA-PK/ATM,在无细胞试验中IC50为16 nM和150 nM。

规格 价格 库存 购买数量  
RMB 899.84 现货
RMB 1414.71 现货
RMB 2210.53 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献21篇:

客户使用该产品的5个实验数据:

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Wortmannin是一种首次命名的PI3K抑制剂,在无细胞试验中IC50为3 nM,对 PI3K 家族的选择性较低。也会抑制自噬体的形成,并有效抑制DNA-PK/ATM,在无细胞试验中IC50为16 nM和150 nM。
靶点
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
体外研究

钙或肽底物不影响Wortmannin对MLCK的抑制,但高浓度的ATP会减弱此种抑制。Wortmannin直接与MLCK催化结构域相互作用,导致不可逆转的酶活性减弱。Wortmannin对cAMP依赖蛋白激酶,cGMP依赖的蛋白激酶,钙调蛋白依赖激酶II,和蛋白激酶C均无抑制作用。[1] Wortmannin抑制由fMLP诱导的PtdInsP3(磷脂酰肌醇3,4,5-三磷酸化)形成,IC 50为5 nM 。在人中性粒细胞中,Wortmannin剂量为100 nM时可发挥完全抑制作用,增加PtdInsP2水平,且对PtdInsP和 PtdIns没有影响;Wortmannin可动态调控F-actin水平对fMLP刺激的肌动蛋白聚合无影响。[2]在RBL-2H3细胞中,Wortmannin通过结合110-kDa蛋白,不可逆的抑制磷酸肌醇3激酶(PI3-kinase)活性(IC 50为3 nM)对,对Pi4-kinase没有影响。Wortmannin也抑制Fc epsilon RI介导的组胺分泌和白三烯释放,对酪氨酸激酶Lyn无影响。[3]在大鼠脂肪细胞中,剂量为0.1 μM的 Wortmannin可完全抑制胰岛素诱导的己糖吸收,二不影响异丙肾上腺素刺激的脂肪分解活性。[4] 在人脐静脉内皮细胞中,在IGF-1的存在下,Wortmannin抑制胰岛素诱导一氧化氮生产,IC50为500nM。[5]在中国仓鼠卵巢细胞中, Wortmannin以50 μM剂量可抑制DNA双链断裂(DSB)修复,但对DSB水平无影响或单链断裂(SSB)酶活无影响。Wortmannin可加强电离辐射(红外)诱导的细胞毒作用,但本身无毒性。[6] Wortmannin抑制水球样激酶(PLK 1)活性,IC 50为24nM,造成细胞G 2 / M阻滞。[7] 在人巨噬细胞中,Wortmannin增加 Toll样受体(TLR)介导的白细胞介素- 6的积累,EC 50 = 50 nM。在小鼠巨噬细胞中,Wortmannin显着增强TLR诱导一氧化氮合酶(iNOS)的表达和亚硝酸盐积累。Wortmannin激活核因子-κB和上调细胞因子mRNA量。[8] Wortmannin也抑制水球样激酶(PlK)1和PlK 3,在有丝分裂中发挥重要作用。Wortmannin治疗可能导致可减少由DNA损伤诱导的p53丝氨酸20位磷酸化。[9] 在SW 1990细胞中,Wortmannin可抑制透明质酸诱导Akt磷酸化和细胞运动/迁移。[10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPxVmRlOi53IN88US=> NX;TdYdYOS12IHS= MlPjSG1UVw>? MoLa[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC2cnXheI1mdnRid3n0bEB1[W2xeHnm[Y4> MlTuNlU1QTB|OEO=
H1703 M4DxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;FVmkzNjVizszN MmrKNU01KGR? M2e2UGROW09? MnjQ[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC2cnXheI1mdnRid3n0bEB1[W2xeHnm[Y4> M2fHVlI2PDlyM{iz
HUVECs MoLwR5l1d3SxeHnjbZR6KEG|c3H5 NVHzdoZnOTByIH7N MVOyOEBp M3XoWIF1fGWwdXH0[ZMhfGinIHHido9o[XSrdnWg[YZn\WO2czDv[kBk[Wy7Y3;zbY4hd25iVmLJMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NEXicWwzPTR3MEG4Oi=>
APRE-19 M3fFZWFxd3C2b4Ppd{BCe3OjeR?= MmLROUDPxE1? M1GySVI1KGh? MWfhZo9tcXOqZYOgSmxbNW2nZHnheIVlKHC{bz3zeZJ3cX[jbD;hcpRqNWGyb4D0c5NqeyCjY4Tpeol1gQ>? NHfLfmUzPTN{OU[xOy=>
MDA-MB-231 NXPFXWF{SXCxcITvd4l{KEG|c3H5 Mne1NeKh|ryPwrC= MX60PEBp M{jwbWROW09? MUjk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygeJJm[XSnZDD3bZRpKDJ3IN88UUBw\iCIMTDvdkBHOiEEoB?= M3y2UVI2OzByOUOy
MCF7 NFzs[3hHfW6ldHnvckBCe3OjeR?= M4DjTlExOCCwTR?= M1r1b|I1KGh? MYflcIlucW6jdHXzJGUzNWmwZIXj[YQhSVKHLVz1Z{Bi[3Srdnn0fS=> MYKyOVE4OjV3Nx?=
HT-29  MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\HS3AzOS53wrFCuW0> NWHyS5d{QTZiaB?= MnnV[IVkemWjc3XzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDpcohq[mm2ZXSgZpkhU1mQQR?= M4POcVI2ODF{MUKz
MO59K  M1vCdWN6fG:2b4jpZ4l1gSCDc4PhfS=> NHriNnM2yqEQvF2= NYDNb5F2PyCm NHH0OlZFVVOR M4fSeIVvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= NV;MTHdmOjR7NUO1OlE>
MO59J M1\tOWN6fG:2b4jpZ4l1gSCDc4PhfS=> NFLJN282yqEQvF2= MX:3JIQ> NFjke2FFVVOR M1jPU4VvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= M4LoclI1QTV|NU[x
MO59K  M1zXV2Fxd3C2b4Ppd{BCe3OjeR?= NED2OJQyOCEQvF2= M3TSU|I1KGh? MmHrSG1UVw>? NV3tbXU5cW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw MV[yOFk2OzV4MR?=
MO59J M{nRUWFxd3C2b4Ppd{BCe3OjeR?= MVGxNEDPxE1? MofCNlQhcA>? M4jYVGROW09? Ml7GbY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv MoPCNlQ6PTN3NkG=
HepG2 NHH0dGlHfW6ldHnvckBCe3OjeR?= M3LufVExOCCwTR?= NET2dpIxNjViaB?= M4H6PWROW09? M2\nVoJtd2OtczDNRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> M2Do[VI1QDZ|M{Ww
A549  M2LYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYqzJOK2VcLi MmraNkBp MVPzeZBxemW|c3XzJJBmdWW2cnX4[YQucW6mdXPl[EBCc3RiYX7kJGdUUzQQsjDhZ5RqfmG2aX;uMEBUNXCqYYPlJIFzemW|dDygZ4VtdCCjcH;weI9{cXNiYX7kJINie3Cjc3WtN{Bi[3SrdnH0bY9v NWf1VXNnOjR6NEe4OlM>
A549  NFHKbIRHfW6ldHnvckBCe3OjeR?= NHv4bm0yOMLizsztxsA> M3HkO|E3KGh? Ml70SG1UVw>? NX7MTmxEdW:mdXzheIV{KHSqZTDJRXYhemWybHnjZZRqd25iYX7kJINifXOnczDy[ZRmdnSrb36gc4YhVlBiaX6geIhmKG63Y3zleZMv MmDJNlQ5ODJzMUG=
SK-N-LO M{KyO2Z2dmO2aX;uJGF{e2G7 NXHESodGOTByIH7N MUCwMlUhcA>? NXHicpFu\GWlcnXhd4V{KHSqZTDzeIlufWyjboSg[YZn\WO2czDv[kBud3KyaHnu[UBwdiCDa4SgdIhwe3Cqb4L5cIF1cW:w M3;Jb|I1PjV2NkC2
HL-60 M3fjbWZ2dmO2aX;uJGF{e2G7 MmnjNE4yyqEQvF2= MmXnO|IhcA>? MXricI9kc3NiZHHzZZRqdmmkLXnu[JVk\WRiY3XscEBlcW[oZYLlcpRq[XSrb36= MXWyOFYxPzJ5Mx?=
HepG2  NXzUWXRSTnWwY4Tpc44hSXO|YYm= M1u1WlIxOCCwTR?= MVqwMlUhcA>? Mnf4ZZR1\W63YYTld{BHd3iRIIDoc5NxcG:{eXzheIlwdg>? M{n0UVI1PTN3MUmy
H520 NIi0ZllHfW6ldHnvckBCe3OjeR?= Ml:xNVDDqM7:TR?= MkfqNUBp NYrvd|dXTE2VTx?= NH3pdlNl\WO{ZXHz[ZMh[2WubIXsZZIheGixc4Doc{1CU1RicILveIVqdiCuZY\lcJM> MXqyOFQ1Pzl|NR?=
H1975 Mn;jSpVv[3Srb36gRZN{[Xl? NImxWHYyOMLizszN M4f1OFEhcA>? NXP0Z29nTE2VTx?= NEX3XJZl\WO{ZXHz[ZMh[2WubIXsZZIheGixc4Doc{1CU1RicILveIVqdiCuZY\lcJM> NGjhVXgzPDR2N{mzOS=>
MG-63 NGHJZYFCeG:ydH;zbZMhSXO|YYm= MY[xNEDDvU1? NHK3UpYyOiCq MXXlcohidmOnczDEVE1qdmS3Y3XkJIFxd3C2b4Ppdy=> MUGyOFM2QDNyMR?=
5637 M1u1PGFxd3C2b4Ppd{BCe3OjeR?= MXKxNOKh|ryP NIj5dW01OCCvaX6= M3j6epJmfmW{c3XzJJAzOVeDRkGg[ZhxemW|c3nvckwhS0SNIHX4dJJme3Orb36sJIFv\CClZXzsJIlvcGmkaYTpc44hcW6mdXPl[EBjgSCodXPvbYRidg>? MYKyOFM{Ozh4OB?=
HEK-293 NHq0SJFHfW6ldHnvckBCe3OjeR?= NH:2THYyPTCwTR?= MkLCNVYhcA>? MnH2SG1UVw>? MkHx[IVkemWjc3XzJGNTXCCjY4Tpeol1gQ>? Mnn5NlQ{OjR|Nk[=
SW480  M2j6fGZ2dmO2aX;uJGF{e2G7 NHPNPHQyPTCwTR?= NF7mS44zOCCq MmnzSG1UVw>? M1;5TpJm\HWlZYOgZ4VtdHWuYYKgZYNkfW23bHH0bY9vKG:oIN8yMYNifGWwaX6= NV7SWXZTOjR|MkSzOlY>
HepG2 MWXGeY5kfGmxbjDBd5NigQ>? MXexNFAhdk1? MmGzNlQhcA>? M{HBOYF1fGWwdXH0[ZMhfGinIHPvcI9vcWW|IH;mJJRp\SC2dX3vdkBk\WyuczD3bZRpKHWycnXneYxifGmxbjDv[kBCc3Rz Mn[3NlQzQTd3MUC=
HCT 116  NWjmcWp6TnWwY4Tpc44hSXO|YYm= NFLDOVkyODBibl2= MVuyOEBp Mn;zZZR1\W63YYTld{B1cGViY3;sc45q\XNib3[geIhmKHS3bX;yJINmdGy|IIfpeIghfXC{ZXf1cIF1cW:wIH;mJGFsfDF? Mn6wNlQzQTd3MUC=
BEL/FU MorZSpVv[3Srb36gRZN{[Xl? MnnSNUBuVQ>? M{XZWVI1KGh? NIjHTYpl\WO{ZXHz[ZMheHKxdHXpckBt\X[nbIOgc4YhfGinIGDJN2swSWu2IIDheIh4[Xl? NI[5dJczPDJ|MkC5PS=>
Huh7  M2XV[mZ2dmO2aX;uJGF{e2G7 NXfnXY9rO8LizszN Mm\CNUBp MVny[YR2[2W|IITo[UB3cXK3czDlcpRzgSCrboTvJJRp\SClZXzsdy=> NFTEcnkzPDF6NEG5Oi=>
A-375 MWrBdI9xfG:|aYOgRZN{[Xl? NFntcpA1NzhizszN NXnFUJdIOjRiaB?= NULRPJZu\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NInX[2kzPDFzM{G3Ny=>
A-375-TS  NWS3OIRISXCxcITvd4l{KEG|c3H5 NWTjd2FoPC96IN88US=> NIfVPWszPCCq Mkj0[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= Mmi3NlQyOTNzN{O=
Mel-HO M3\qbGFxd3C2b4Ppd{BCe3OjeR?= M{XaXlQwQCEQvF2= MkHpNlQhcA>? MYrlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5Nqe8Li MVqyOFEyOzF5Mx?=
Mel-HO-TS NF7Hb4RCeG:ydH;zbZMhSXO|YYm= NVf0WFJWPC96IN88US=> M4f0cVI1KGh? NInybItmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NULn[lFqOjRzMUOxO|M>
MeWo NIS4N4ZCeG:ydH;zbZMhSXO|YYm= MX:0M|gh|ryP Mnn0NlQhcA>? NGDoU3FmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MWKyOFEyOzF5Mx?=
Mel-2a NULhRlNHSXCxcITvd4l{KEG|c3H5 NX\ifJhTPC96IN88US=> Mo\nNlQhcA>? NIO1XoJmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NHzHTpozPDFzM{G3Ny=>
MDA-MB-231 MUjGeY5kfGmxbjDBd5NigQ>? NEn3N4Yx6oDVNECwJI5O NHrUWmo1KGh? Mk\Wd5VxeHKnc4Pld{BCc3RicHjvd5Bpd3K7bHH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2rmcVIzQTB4MkW5
MDA-MB-231 MVrGeY5kfGmxbjDBd5NigQ>? NIXiSpU1ODBibl2= MWm0JIg> MYLk[YNz\WG|ZYOgUW1RNTliYX7kJGlNNThicILveIVqdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MX2yNlkxPjJ3OR?=
Jurkat NILmN2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXHNE4zPS1zLkK1JO69VQ>? MkDFNlQwPDhiaB?= NWTWPWd4TE2VTx?= NVPnNWJMcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= MojVNVk4PTdzOEW=
Namalwa MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHBWXJwOC5{NT2xMlI2KM7:TR?= MYGyOE81QCCq MV7EUXNQ MVrpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36gbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>? NWrJeJpiOTl5NUexPFU>
Jurkat NFzuO4RCeG:ydH;zbZMhSXO|YYm= MXywMlI2NTFwMkWg{txO M2e0[VI1NzR6IHi= MUTEUXNQ MX\pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= NFfUZXEyQTd3N{G4OS=>
Namalwa MV\BdI9xfG:|aYOgRZN{[Xl? M{H1[FAvOjVvMT6yOUDPxE1? Mo\3NlQwPDhiaB?= M2T1XWROW09? M3HhdIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> NHXzc3IyQTd3N{G4OS=>
K562 NGTIUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrHbYVTOjRiaB?= Mo\6TWM2OD1{NdMxNE4yPCCwTR?= MVSxPVY3OjN4MR?=
SW1990 NVfRS4UzTnWwY4Tpc44hSXO|YYm= M3\RZlAvODFvMTFOwG0> MYOxJIg> NX6zTYxWcW6qaXLpeJMhUEFvaX7keYNm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w MXmxPVQ3QTB{MB?=
RT112  NFj4SoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKxNOKh|ryP NUTa[mJiOjRiaB?= MVPEUXNQ NHv4W5Bl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? MV[xPFc5Pzh|Mh?=
MHG-U1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rJdFExyqEQvF2= NU[2NXVGOjRiaB?= MWTEUXNQ M1Gy[IRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBIOi:PIHPlcIx{ NXfESoxpOTh5OEe4N|I>
SMMC-7721 MnS4RZBweHSxc3nzJGF{e2G7 MmTsNlAxyqCwTR?= NFjHcXkzPCCq NVnEe25FcW6lcnXhd4V{KEOKWD3pcoR2[2WmIHHwc5B1d3Orcx?= NFHEeHIyPzV3N{G5NS=>
SMMC-7721 MkfKSpVv[3Srb36gRZN{[Xl? NYfWb|JwOjBywrDuUS=> NH;yV5czPCCq Mnn2eZAuemWpdXzheIV{KM7{MTy0S3QyKGW6cILld5Nqd25? MlT0NVc2PTdzOUG=
HeLa M33WUmZ2dmO2aX;uJGF{e2G7 NIPENJkyODEEoH7NxsA> MU[xJIg> NWTnd3dl[Wy2ZYLzJJRp\SCvb4LwbI9td2e7IH;mJJRp\SC2cnHud4ZmenKrbjDy[YN6[2yrbnegZ49ueGG{dH3lcpQ> NWP0fnZnOTZ6OUC5NVU>
MRC5VI NEXCb3lHfW6ldHnvckBCe3OjeR?= MWexNk42KG2P NGO4d20xNjViaB?= MVnEUXNQ MX3hZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> M4LoXVE3OjJ5M{m0
AT5BIVA NFHNUJJHfW6ldHnvckBCe3OjeR?= M3T5NlEzNjVibV2= M3\vUlAvPSCq NY\XeGxwTE2VTx?= NYnLdVNq[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? Ml7zNVYzOjd|OUS=
M059J MnPPSpVv[3Srb36gRZN{[Xl? NXfMV2RZOTJwNTDtUS=> MVewMlUhcA>? MnTySG1UVw>? M37kcYFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh NFvtcZkyPjJ{N{O5OC=>
HeLa M1vVcWZ2dmO2aX;uJGF{e2G7 NIrjR20yOi53IH3N M3rsZlAvPSCq NWPjVGNwTE2VTx?= NX;JWWND[WKxbHnzbIV{KHSqZTDT[ZI1PzNxVHjyN|A5yqCyaH;zdIhwenmuYYTpc44hd2ZiQXv0VGtDyqB? NFXUSmkyPjJ{N{O5OC=>
N2a MUHBdI9xfG:|aYOgRZN{[Xl? NV3sNGlCOC5zLUGwJO69VQ>? NVTwbIo2OiCq M1uw[4lv\HWlZYOg[IVkemWjc3XkJINmdGxidnnhZoltcXS7IHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ MU[xOVg1Ojd4Nx?=
Jurkat  NGDCN|NMcW6jc3WgRZN{[Xl? NVv2WG5MUUN3MDDv[kAzPCCwTR?= M3KzVVE2PjZ2NUG5

... Click to View More Cell Line Experimental Data

体内研究 Wortmannin剂量为1mg/kg可抑移植瘤小鼠中SW1990的腹膜转移,无重量损失。[10] Wortmannin抑制在小鼠正常组织(肺,心脏和脑组织匀浆)及肿瘤组织中的phosphatidylinositide 3- B激酶(PKB)/磷酸化Akt,在剂量为0.7 mg/kg时无死亡或急性毒性。与gemcitabine联合使用时,可大大增加细胞凋亡和抑制原位肿瘤生长,两种药物单独使用都无以上效果。[11]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[11]
+ 展开
  • Animal Models: 人胰腺癌细胞 PK1s.c.和原位注入SCID免疫缺陷小鼠。
  • Formulation: 0.4 mg/mL 溶于 DMSO, 使用时用 0.9% NaCl 稀释
  • Dosages: 0.175, 0.35, 和0.7 mg/kg
  • Administration: 静脉注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 428.43
化学式

C23H24O8

CAS号 19545-26-7
稳定性 powder
in solvent
别名 KY 12420

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Wortmannin | Wortmannin供应商 | 采购Wortmannin | Wortmannin价格 | Wortmannin生产 | 订购Wortmannin | Wortmannin代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID